| | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
|---|
Age (y) | 60.8 | 34.4 | 23.7 | 29.8 |
Sex (m/f) | f | f | f | m |
Diagnosis | Seropositive RA | Seropositive RA | SLE polyarthritis | AS |
Disease duration (y) | 31 | 15 | 5 | 7 |
DAS28 | 3.50 | 3.35 | – | – |
BASDAI | – | – | – | 2.3 |
BASMI | – | – | – | 2 |
SLEDAI | – | – | 12 | – |
ESR (1 h) | 30 mm | 4 mm | 54 mm | 4 mm |
CRP (mg/dl) | 0.25 | 0.01 | 0.04 | 0.31 |
Leukocytes (n*1000/µl) | 9.9 | 6.7 | 6.4 | 12.8 |
Remission (yes/no) | No | No | No | Yes |
Methotrexate | 10 mg 1x/week | – | – | – |
Leflunomide | 20 mg 1–0-0 | – | – | – |
Prednisolone | 40 mg 1–0-0 | 7.5 mg 1–0–0 | 40 mg 1–0–0 | – |
Infliximab | – | – | – | 400 mg 1 × /8 weeks |
Mycophenolate mofetil | – | – | 500 mg 2–0–2 | – |
Etanercept | – | 50 mg 1x/week | – | – |
- Table shows age in years (y); sex—male/female (m/f); Diagnosis (RA = rheumatoid arthritis, SLE = systemic lupus erythematosus, AS = ankylosing spondylitis); Years since initial diagnosis; Disease Activity Score 28 (DAS28); Bath Ankylosing Spondylitis Disease Activity Index (BASDAI); Bath Ankylosing Spondylitis Metrology Index (BASMI); Systemic Lupus Erythematosus Disease Activity Index (SLEDAI); Erythrocyte sedimentation rate (ESR) after one hour (1 h); C-reactive protein (CRP) in mg/dl; Leukocytes in n*1000/µl; Medication at the time of blood sample collection (MTX = methotrexate, LEF = leflunomide, PRE = prednisolone, ETA = etanercept, MYC = mycophenolate mofetil, INF = infliximab); Remission yes/no (patient in remission phase yes or no). A DAS28 < 2.6 was defined as remission for patients 1 and 2. Patient 3 showed an increased disease activity corresponding to a total of 12 points in the SLEDAI. In patient 4, a remission of the underlying disease could be assumed on the basis of low numerical values in the BASDAI and BASMI
